<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02114333</url>
  </required_header>
  <id_info>
    <org_study_id>13-3192</org_study_id>
    <nct_id>NCT02114333</nct_id>
  </id_info>
  <brief_title>Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds</brief_title>
  <official_title>A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the GSK Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the two vaccines that have been developed to prevent and/or lessen
      the effects of shingles.  One vaccine is live (Zostavax, licensed by FDA) and the other
      (HZ/su) contains a piece of the shingles virus (not live) and an ingredient that may enhance
      the body's response to the vaccine, and is currently investigational.  The vaccines are
      being compared to assess their ability to stimulated protection against shingles.  The study
      will provide an opportunity to determine the safety profile of each vaccine in a single
      trial.  The study will also look at the effect of age on the immune response to the two
      vaccines and on the persistence of these responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Interferon gamma/ Interleukin 2 (IFNg/IL2) dual color fluorospot number</measure>
    <time_frame>Measured up to  Day  730</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>glycoprotein-based enzyme-linked immunosorbent assay (gpELISA)</measure>
    <time_frame>Measured up to Day 730</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Within 30 days of each vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Adult</condition>
  <condition>Shingles</condition>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No previous zoster vaccine; stratified between age groups 50-59 and 70-85
First dose live vaccine, Zostavax (0.65ml, subcutaneous)
Second dose placebo, normal saline (0.65ml. subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - recombinant zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No previous zoster vaccine; stratified between age groups 50-59 and 70-85
First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One previous dose of zoster vaccine at least 5 years previously, age 70-85
First dose live vaccine, Zostavax (0.65ml, subcutaneous)
Second dose placebo, normal saline (0.65ml. subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - recombinant zoster vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One previous dose of zoster vaccine at least 5 years previously, age 70-85
First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>0.65ml, subcutaneous</description>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HZ/su vaccine</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>B - recombinant zoster vaccine</arm_group_label>
    <arm_group_label>D - recombinant zoster vaccine</arm_group_label>
    <other_name>Recombinant vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.65ml, subcutaneous</description>
    <arm_group_label>A - Live zoster vaccine</arm_group_label>
    <arm_group_label>C - Live zoster vaccine</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of varicella or residence int he US for 30 years

          -  For Arms C and D - prior live zoster vaccine at least 5 years previously

          -  For Arms A and B - Age 50-59 or 70-85

          -  For Arms C and D - Age 70-85

          -  For women of childbearing potential, a negative pregnancy test and     agreement to
             use adequate contraception from 30 days before until 3 months after the last dose of
             any study vaccine

        Exclusion Criteria:

          -  History of herpes zoster

          -  For Arms A and B - prior live zoster vaccine

          -  Immune compromising illness or therapies or chronic illness

          -  Allergy to previous herpes zoster vaccine

          -  Other investigational drugs or vaccines within the past 6 months before the study and
             until last visit

          -  Blood products for 3 months prior to or planned during the study

          -  Concomitant non-topical antiviral therapy within 3 days prior to and 7 days after
             vaccination.

          -  Vaccines within 2 weeks (inactive vaccine) or 4 weeks (live vaccine) prior to the
             study until 30 days after any dose of either vaccine.

          -  Pregnancy or breast-feeding

          -  Current drug addiction or alcoholism.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron J Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Lang, BSN</last_name>
    <phone>303-724-2454</phone>
    <email>nancy.lang@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lang, BSN</last_name>
      <phone>303-724-2454</phone>
      <email>nancy.lang@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Myron J Levin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shingles vaccine</keyword>
  <keyword>Immune response</keyword>
  <keyword>Zoster vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
